Pancreatic cancer mRNA vaccine shows durable responses in early trial

In a small phase I trial, a personalized mRNA vaccine given to patients with operable pancreatic tumors produced durable responses, and nearly all patients WHO responded were still alive six years later. That result stands against the usual prognosis, since fewer than 13 percent of people with pancreatic cancer survive five years after diagnosis. The study enrolled only surgically resectable cases, and investigators say larger randomized trials are needed to confirm whether the vaccine produces a true survival benefit.